In the I-SPY2 neoadjuvant trial, neratinib in combination with trastuzumab resulted in an improvement in the pathologic complete response (pCR) rate in HER2-positive, hormone receptor (HR)-negative BC patients(Park et al. 2016; Stoen et al. 2021). The gene discussed is ERBB2; the disease is breast cancer.